BioMarin Unveils Promising Data on VOXZOGO for Young Children with Achondroplasia at ACMG 2025
BioMarin Unveils Promising Data on VOXZOGO for Young Children with Achondroplasia at ACMG 2025
In an exciting presentation at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting held in Los Angeles, BioMarin Pharmaceutical Inc. showcased new data regarding VOXZOGO® (vosoritide), a groundbreaking treatment for achondroplasia in young children. This information is crucial as it highlights both the positive safety profile of the drug and its efficacy in maintaining treatment adherence in real-world clinical settings.
Key Findings on VOXZOGO’s Safety and Effectiveness
In a clinical study conducted in Japan involving 63 children under the age of three with achondroplasia, VOXZOGO displayed remarkable treatment adherence with no reported adverse events related to the therapy throughout the observation period, which extended up to 23.7 months. These outcomes are significant as they reinforce the established safety profile of VOXZOGO, suggesting that the treatment is not only effective but also well-tolerated, even among infants as young as one month old.
"VOXZOGO is the first and only approved treatment aimed specifically at addressing the challenges posed by achondroplasia, and the results showing favorable safety and adherence are very encouraging," remarked Dr. Greg Friberg, executive vice president and chief research development officer at BioMarin. "Given that the impacts of restricted growth can be evident from birth, initiating treatment at an earlier age may result in enhanced benefits for these young patients."
Broader Research and Future Studies
In addition to findings pertaining to VOXZOGO, the conference also featured data regarding PALYNZIQ® (pegvaliase-pqpz), another BioMarin product designed for adults with phenylketonuria (PKU). The OPAL study revealed positive results, including significant reductions in blood phenylalanine (Phe) levels and improvements in health-related quality of life measures for adults undergoing this treatment.
The new data from BioMarin underscores the company's commitment not only to developing effective therapies but also to advancing our understanding of various genetic conditions. This includes ongoing studies on skeletal conditions related to achondroplasia, such as hypochondroplasia. BioMarin anticipates completing enrollment for pivotal studies in the first half of 2025, signifying ongoing advancements in research and treatment options.
Insights from the Latest Studies
The presentation of data at ACMG included several noteworthy studies:
- - VOXZOGO Safety Profile: The research presented demonstrates strong adherence to VOXZOGO and a significant absence of negative side effects.
- - Sustained Phe Level Reduction with PALYNZIQ: Analysis from the OPAL study showed that the mean Phe levels in participants reduced from 1029 μmol/L at baseline to 293 μmol/L after 96 weeks, highlighting the therapy's effectiveness in managing PKU.
- - Quality of Life Measures: Health-related quality of life improvements were also documented, underscoring the broader impacts of sustained lower Phe levels on cognitive and emotional well-being.
The emphasis on these data points is indicative of BioMarin's strategy to support both pediatric and adult populations affected by genetically defined conditions. By providing real-world evidence of the therapy's benefits, the company aims to foster a greater understanding and acceptance of these treatments within the medical community.
Conclusion
As the landscape of genetic therapies continues to evolve, BioMarin remains at the forefront, offering hope and improved quality of life for individuals affected by conditions like achondroplasia and PKU. The data presented at ACMG 2025 not only validates the utility of VOXZOGO and PALYNZIQ, but also underscores the importance of early intervention and sustained adherence in the pursuit of better health outcomes.
For further information regarding VOXZOGO and PALYNZIQ, or to learn more about BioMarin's ongoing research efforts, please visit BioMarin's website for more details.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.